-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 2023 OCALA EQUINE CONFERENCE IN OCALA, FLORIDA
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 2023 OCALA EQUINE CONFERENCE IN OCALA, FLORIDA
MINNEAPOLIS, Jan. 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the 2023 FAEP Ocala Equine Conference from January 21st to January 22nd, 2023 at the World Equestrian Center in Ocala, FL.
"We are looking forward to networking with the experts and leaders in the equine industry and develop relationships that will help drive forward our innovative veterinary medical device for the treatment of osteoarthritis, Spryng™, with OsteoCushion™ Technology" said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit
Conference Details:
2023 Ocala Equine Conference
Booth #: 15
Dates:
Saturday, January 21, 2023 9:40am – 5:40pm
Sunday, January 22, 2023 9:40am – 1:10pm
Location: World Equestrian Center, Exposition Center 1
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products at various stages of development and/or commercialization for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company's common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
MINNEAPOLIS, Jan. 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the 2023 FAEP Ocala Equine Conference from January 21st to January 22nd, 2023 at the World Equestrian Center in Ocala, FL.
明尼阿波利斯,2023年1月17日(环球社)--PetVivo控股公司(纳斯达克代码:PETV&PETVW)今天宣布,它将参加从1月21日起举行的2023年FAEP奥卡拉马术大会(FAEP Ocala Equine Conference)。ST至1月22日发送,2023年,在佛罗里达州奥卡拉的世界马术中心。
"We are looking forward to networking with the experts and leaders in the equine industry and develop relationships that will help drive forward our innovative veterinary medical device for the treatment of osteoarthritis, Spryng™, with OsteoCushion™ Technology" said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
PetVivo控股公司首席执行官约翰·赖说:“我们期待着与马匹行业的专家和领先者建立联系,发展关系,这将有助于推动我们治疗骨关节炎的创新兽医设备Spryng™与OsteoCushion™技术的发展。
Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
Spryng是一种可注射的兽医设备,由数百万微粉化的细胞外基质颗粒组成,这些颗粒来自天然成分,包括胶原和弹性蛋白。OsteoCushion技术既提供增强的自然关节支撑,以增强和/或增强丢失和/或损坏的软骨,也提供自然支架,以帮助解决组织缺陷。这些属性提供了一个很好的解决方案来管理跛行和关节痛苦,如骨关节炎,在一个简单的诊所给药的同伴动物。
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit
欲获知更多有关PetVivo控股公司的信息,请联系info1@petvivo.com或访问
Conference Details:
会议详细信息:
2023 Ocala Equine Conference
2023年奥卡拉马术大会
Booth #: 15
展位号:15
Dates:
日期:
Saturday, January 21, 2023 9:40am – 5:40pm
2023年1月21日(星期六)上午9:40至下午5:40
Sunday, January 22, 2023 9:40am – 1:10pm
2023年1月22日(星期日)上午9:40至下午1:10
Location: World Equestrian Center, Exposition Center 1
地点:世界马术中心、世博中心1号
About PetVivo Holdings, Inc.
关于PetVivo控股公司
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo控股公司(纳斯达克代码:PETV&PETVW)是一家新兴的生物医疗设备公司,目前专注于为同伴动物制造、商业化和许可创新的医疗设备和治疗药物。该公司的战略是利用人类疗法以一种既省钱又省时的方式治疗同伴动物。这一战略的一个关键组成部分是加快兽医医疗设备收入的时间表,这些设备进入市场的时间比监管更严格的药品和生物制品早得多。
PetVivo has a robust pipeline of products at various stages of development and/or commercialization for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
PetVivo在动物和人类治疗的不同开发和/或商业化阶段拥有强大的产品流水线。共有19项专利保护该公司的生物材料、产品、生产工艺和使用方法。该公司的主导产品Spryng™采用OsteoCushion™技术,这是一种由兽医管理的关节内注射,用于治疗狗和马的跛行和其他关节相关疾病,包括骨关节炎,目前正在进行商业销售。
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit
欲了解有关PetVivo控股公司和我们的革命性产品Spryng with OsteoCushion Technology的更多信息,请联系info1@petvivo.com或访问
CONTACT:
联系方式:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
首席执行官黎智英
PetVivo控股公司
电子邮件:info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
前瞻性商业声明:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company's common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
上述材料可能包含1933年《证券法》第27A节和1934年《证券交易法》第21E节(均经修订)所指的“前瞻性陈述”。前瞻性陈述包括所有不完全与历史或当前事实有关的陈述,包括但不限于公司建议的开发和商业时间表,可以通过使用“可能”、“将”、“预期”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续”或这些词语的否定版本或其他类似词语来识别。前瞻性陈述不是对未来行动或业绩的保证。这些前瞻性陈述,包括公司普通股可能在纳斯达克上市的可能性,是基于公司及其当前计划或预期的现有信息,会受到一些不确定性和风险的影响,这些不确定性和风险可能会对现有计划产生重大影响。与公司业务有关的风险在公司截至2022年3月31日的10-K表格年度报告以及提交给证券交易委员会的其他定期报告和当前报告中有详细描述。无论是由于新信息、未来事件或其他原因,公司没有义务更新或改变其前瞻性陈述,并明确表示不承担任何此类义务。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧